In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.04% change from the preceding trading day.

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

Patients who received Lilly’s pill did not show signs of liver damage, the company said. Liver side effects scuttled Pfizer’s ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & ...

Citi analyst Daniel Grosslight maintained a Hold rating on Cardinal Health (CAH – Research Report) today and set a price target of $140.00. The ...

BofA Securities reiterated its Underperform rating on Hims & Hers Health (NYSE:HIMS), keeping its price target steady at $22, ...

Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...